New model may predict and prevent deadly transplant complication
NCT ID NCT07588945
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving the drug ruxolitinib early can prevent severe graft-versus-host disease (GvHD) in people getting a stem cell transplant. About 438 adults at intermediate-to-high risk, as identified by a special model called daGOAT, will be enrolled. The goal is to see if this approach reduces severe GvHD within the first 100 days after transplant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSPLANT-RELATED DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New bedside test may cut blood transfusions in lung transplants
- New hope for transplant patients: easier CMV prevention on the horizon?
- Can we predict diabetes after a liver transplant?
- Nerve check may predict transplant complication risk
- New cell prep method aims to tame transplant complications in kids
- Radioactive antibody could boost stem cell transplant success in tough leukemia